Detalhe da pesquisa
1.
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.
Case Rep Oncol
; 9(1): 45-50, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933418
2.
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.
Case Rep Oncol
; 9(1): 62-7, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933421
3.
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.
Case Rep Oncol
; 9(1): 171-6, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27065849
4.
Dysphonia after Bevacizumab Rechallenge: A Case Report.
Case Rep Oncol
; 8(3): 423-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26600773
5.
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.
Case Rep Oncol
; 8(3): 461-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26600780
6.
Follow the ATP: tumor energy production: a perspective.
Anticancer Agents Med Chem
; 14(9): 1187-98, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25102360